(Q44599299)

English

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial

scientific article published on 9 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

prostate adenocarcinoma

1 reference

based on heuristic

inferred from title

Philip W. Kantoff

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

author name string

Paul F Schellhammer

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Gerald Chodak

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

James B Whitmore

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Robert Sims

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Mark W Frohlich

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

0 references

publication date

9 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

81

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1297-1302

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Sipuleucel-T: in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Pathogenesis and treatment of anaemia of chronic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Cytokines and their relationship to the symptoms and outcome of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

The tumor microenvironment and its role in promoting tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.061

7 January 2021

Identifiers

10.1016/J.UROLOGY.2013.01.061

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44599299&oldid=2029105064"